Must every child with long QT syndrome take a beta blocker?

Archives of Disease in Childhood

Volumn 100, Issue 3, 2015, Pages 279-282

  Waddell Smith, Kathryn E ^a,b   Earle, Nikki ^b   Skinner, Jonathan R ^a,b,c  

^a STARSHIP CHILDREN S HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; POTASSIUM CHANNEL KCNH2; POTASSIUM CHANNEL KCNQ1; SODIUM CHANNEL NAV1.5; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ASYMPTOMATIC DISEASE; CHILD; CONSENSUS; DRUG EFFICACY; ELECTROCARDIOGRAM; FAINTNESS; GENOTYPE; HEART ARREST; HEART RATE; HIGH RISK BEHAVIOR; HUMAN; LONG QT SYNDROME; LONG QT SYNDROME 1; LONG QT SYNDROME 2; MISSENSE MUTATION; PRACTICE GUIDELINE; PREPUBERTY; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; REVIEW; SOCIAL PSYCHOLOGY; SUDDEN CARDIAC DEATH; SWIMMING; FEMALE; GENETICS; MALE; MUTATION; PRESCHOOL CHILD;

ADRENERGIC BETA-ANTAGONISTS; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; HUMANS; LONG QT SYNDROME; MALE; MUTATION;

EID: 84923346024     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2014-306864     Document Type: Review

References (35)

1. Schwartz PJ, Stramba-Badiale M, Crotti L, et al. Prevalence of the congenital long-QT syndrome. Circulation 2009;120:1761-7.
2. Skinner JR, Crawford J, Smith W, et al. Prospective, population-based long QT molecular autopsy study of postmortem negative sudden death in 1 to 40-year-olds. Heart Rhythm 2011;8:412-19.
3. van der Werf C, Hofman N, Tan HL, et al. Diagnostic yield in sudden unexplained death and aborted cardiac arrest in the young: the experience of a tertiary referral center in The Netherlands. Heart Rhythm 2010;7:1383-9.
4. Tester DJ, Medeiros-Domingo A, Will ML, et al. Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing. Mayo Clin Proc 2012;87:524-39.
5. MacCormick JM, McAlister H, Crawford J, et al. Misdiagnosis of long QT syndrome as epilepsy at first presentation. Ann Emerg Med 2009;54:26-32.
6. Albertella L, Crawford J, Skinner JR. Presentation and outcome of water-related events in children with long QT syndrome. Arch Dis Child 2011;96:704-7.
7. MacCormick JM, Crawford JR, Chung SK, et al. Symptoms and signs associated with syncope in young people with primary cardiac arrhythmias. Heart Lung Circ 2011;20:593-8.
8. Arnestad M, Crotti L, Rognum TO, et al. Prevalence of long-QT syndrome gene variants in sudden infant death syndrome. Circulation 2007;115:361-7.
9. Goldenberg I, Moss AJ, Bradley J, et al. Long-QT syndrome after age 40. Circulation 2008;117:2192-201.
10. Earle N, Crawford J, Smith W, et al. Community detection of long QT syndrome with a clinical registry: an alternative to ECG screening programs? Heart Rhythm 2013;10:233-8.
11. Theilade J, Kanters J, Henriksen FL, et al. Cascade screening in families with inherited cardiac diseases driven by cardiologists: feasibility and nationwide outcome in long QT syndrome. Cardiology 2013;126:131-7.
12. Vincent GM, Schwartz PJ, Denjoy I, et al. High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures". Circulation 2009;119:215-21.
13. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006;27:1153-8.
14. Kalra PR, Morley C, Barnes S, et al. Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study. Int J Cardiol 2012;167:2695-9.
15. Dimsdale JE, Newton RP. Cognitive effects of beta blockers. J Psychosom Res 1992;36:229-36.
16. Lewis RV, Jackson PR, Ramsay LE. Side-effects of beta-blockers assessed using visual analogue scales. Eur J Clin Pharmacol 1985;28(Suppl):93-6.
17. Barron AJ, Zaman N, Cole GD, et al. Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol 2013;168:3572-9.
18. Goldenberg I, Moss AJ, Peterson DR, et al. Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation 2008;117:2184-91.
19. Hobbs JB, Peterson DR, Moss AJ, et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA 2006;296:1249-54.
20. Sauer AJ, Moss AJ, McNitt S, et al. Long QT syndrome in adults. J Am Coll Cardiol 2007;49:329-37.
21. Goldenberg I, Thottathil P, Lopes CM, et al. Trigger-specific ion-channel mechanisms, risk factors, and response to therapy in type 1 long QT syndrome. Heart Rhythm 2011;9:49-56.
22. Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol 2011;57:51-9.
23. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes: Document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 2013;10:1932-63.
24. Barsheshet A, Goldenberg I, O-Uchi J, et al. Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to beta-blocker therapy in type 1 long-QT syndrome. Circulation 2012;125:1988-96.
25. Costa J, Lopes CM, Barsheshet A, et al. Combined assessment of sex- and mutation-specific information for risk stratification in type 1 long QT syndrome. Heart Rhythm 2012;9:892-8.
26. Seth R, Moss AJ, McNitt S, et al. Long QT syndrome and pregnancy. J Am Coll Cardiol 2007;49:1092-8.
27. Migdalovich D, Moss AJ, Lopes CM, et al. Mutation and gender-specific risk in type 2 long QT syndrome: implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome. Heart Rhythm 2011;8:1537-43.
28. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001;103:89-95.
29. Calvillo L, Spazzolini C, Vullo E, et al. Propranolol prevents life-threatening arrhythmias in LQT3 transgenic mice: implications for the clinical management of LQT3 patients. Heart Rhythm 2014;11:126-32.
30. Ruan Y, Liu N, Bloise R, et al. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation 2007;116:1137-44.
31. Wedekind H, Burde D, Zumhagen S, et al. QT interval prolongation and risk for cardiac events in genotyped LQTS-index children. Eur J Pediatr 2009;168:1107-15.
32. Sedlak T, Shufelt C, Iribarren C, et al. Sex hormones and the QT interval: a review. J Womens Health (Larchmt) 2012;21:933-41.
33. Goldenberg I, Mathew J, Moss AJ, et al. Corrected QT variability in serial electrocardiograms in long QT syndrome: the importance of the maximum corrected QT for risk stratification. J Am Coll Cardiol 2006;48:1047-52.
34. Johnson JN, Ackerman MJ. Return to play? Athletes with congenital long QT syndrome. Br J Sports Med 2013;47:28-33.
35. Chockalingam P, Crotti L, Girardengo G, et al. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol 2012;60:2092-9.